NeuroSense Therapeutics shares are trading lower. The company announced the availability of additional long-term survival data from its PARADIGM Phase 2b clinical trial evaluating PrimeC.
Neurosense Therapeutics Ltd. -3.01%
Neurosense Therapeutics Ltd. NRSN | 0.71 | -3.01% |
NeuroSense Therapeutics shares are trading lower. The company announced the availability of additional long-term survival data from its PARADIGM Phase 2b clinical trial evaluating PrimeC.
